2015 American Transplant Congress » Poster Session D: Kidney Immunosuppression: Drug Minimization

Date: Tuesday, May 5, 2015

Time: 5:30pm-6:30pm

Location: Exhibit Hall E

Session Type: Poster Session

Meeting: 2015 American Transplant Congress

5:30pm-6:30pm: "What's the Mileage?" Determining the Length of Time in Which Renal Function Returns to Pre-Calcineurin Discontinuation Levels in Patients With Interstitial Fibrosis

A. Diez, J. Von Visger, U. Nori, T. Pesavento, M. Henry, E. Davies, R. Pelletier.

5:30pm-6:30pm: 12-Month Athena Study: Everolimus Vs. Standard Regimen in De Novo Renal Transplant Recipients

C. Sommerer,¹ B. Suwelack,¹ D. Dragun,¹ I. Hauser,¹ P. Schenker,¹ D. Bäumer,² B. Nashan,¹ F. Thaiss.¹

5:30pm-6:30pm: 2-Year Results on Renal Function and Safety for Everolimus plus Reduced-Exposure Calcineurin Inhibitor in Living Donor Kidney Transplant Recipients

T. Yagisawa,¹ N. Ishikawa,¹ N. Goto,² I. Nakajima,³ O. Kamisawa,⁴ S. Fuchinoue.³

5:30pm-6:30pm: 24 Month Post Transplantation Follow Up of the Certitem Trial

E. Rondeau,¹ E. Cassuto,² V. Vuiblet,³ C. Legendre,⁴ P. Merville,⁵ Y. Le Meur,⁶ B. Moulin,⁷ P. Westeel,⁸ B. Hurault De Ligny,⁹ A. Lécuyer,¹⁰ M. Tindel,¹¹ N. Kamar.¹²

5:30pm-6:30pm: A 52-Week, Multicenter, Prospective, Observational, Non-Interventional, Open-Label Study to Assess the Effectiveness, Safety and Tolerability of Everolimus in Kidney Transplant Patients in Taiwan

S.-M. Wang,¹ P.-C. Lee,² J.-D. Lian,³ K.-H. Shu,⁴ S.-T. Wu,⁵ H.-C. Chen,⁶ C.-C. Huang,⁷ M.-S. Wu,⁸ Y.-C. Tian,⁹ Y.-J. Chiang,¹⁰ Y.-T. Chen,¹¹ H.-P. Wang.¹²

5:30pm-6:30pm: Acute Kidney Injury in the MELD Era of Liver Transplantation. Are Calcineurin Inhibitors So Problematic for Renal Function?

R. Ciria Bru, I. Gómez Luque, M. Cortés Cerisuelo, P. López Cillero, J. O'Grady, M. de la Mata, N. Heaton, J. Briceño Delgado.

5:30pm-6:30pm: Calcineurin Inhibitor-Free Immunossupresion After Kidney Transplantation, Using Everolimus De Novo – Single Center Experience

M. Stronka, Z. Adamska, L. Cichanska, J. Kubiak, M. Gamrat, M. Karczewski.

5:30pm-6:30pm: Calcineurin Inhibitors (CNI) Minimization Associated With Mammalian Target of Rapamycin Inhibitors (i-mTOR) to Improve Renal Function in Renal Grafts from Uncontrolled Donation After Cardiac Death Donors (UDCDD)

M. Molina,¹ E. Gutierrez,¹ S. González-Sanchidrian,² E. González,¹ J. Cabrera,¹ N. Polanco,¹ A. Hernández,¹ A. Sevillano,¹ M. Praga,¹ A. Andres.¹

5:30pm-6:30pm: Calcineurin-Inhibitor Conversion to mTOR Inhibitor in Renal Transplant Recipients Leads to Worse Long Term Clinical Outcomes

A. Alvarado,¹ A. Shetty,¹ O. Traitanon,¹ J. Leventhal,¹ V. Mas,² D. Chhabra,³ J. Matthews,¹ L. Gallon.¹

5:30pm-6:30pm: Comparison of Efficacy and Renal Function in KidneyTransplant Recipients Receiving Tacrolimus (TAC)-Based Immunosuppressive Regimens in Combination With Everolimus (EVR) or Mycophenolate (MPA)

A. Ferreira,¹ C. Felipe,¹ P. Ueno,¹ P. Hannun,¹ P. Ruppel,¹ T. Sandes-Freitas,¹ H. Proença,³ J. Medina- Pestana,¹ H. Tedesco-Silva.¹

5:30pm-6:30pm: Conversion from Immediate to Prolonged Release Tacrolimus Did Not Change Intra-Patient Variability in Renal Transplant Patients

T. El-Nahhas,^1,2 M. Moreton,² J. Popoola,³ S. Abat,³ A. Johnston,^1,2 I. MacPhee.³

5:30pm-6:30pm: Delayed Tacrolimus (TAC) to Rapamycin (RAPA) Conversion in Renal Transplant Recipients With DGF/SGF

A. Haririan,¹ D. Klassen,¹ M. Keshtkar,¹ C. Drachenberg,² T. Dowling,³ E. Ramos,¹ R. Ugarte,¹ C. Cangro,¹ M. Weir.¹

5:30pm-6:30pm: Early Steroid Withdrawal and Calcineurin Inhibitor Minimization Protocols for Maintenance Immunosuppression: A Single Center 10-Year Experience

R. Lopez-Soler,¹ L. Park,³ J. Martinolich,² D. Conti.¹

5:30pm-6:30pm: Early Steroid Withdrawal and Infection Risk in Kidney Transplant Recipients

S. Bae, L. Kucirka, C. Durand, B. Orandi, R. Avery, D. Segev.

5:30pm-6:30pm: Everolimus Plus Reduced-Exposure Calcineurin Inhibitor Versus Mycophenolate Mofetil Plus Standard-Exposure Calcineurin Inhibitor: 2-Year Results in Living Donor Kidney Transplant Recipients

Y. Watarai,¹ N. Akutsu,² K. Saito,³ Y. Nakagawa,³ O. Kamisawa,⁴ T. Kenmochi.⁵

5:30pm-6:30pm: Explorative Analysis of ZEUS After 5 Years: Histological Assessment from Biopsy Analyses

U. Eisenberger,¹ K. Budde,¹ O. Witzke,¹ F. Lehner,¹ C. Sommerer,¹ R. Wuethrich,³ P. Reinke,¹ A. Muehlfeld,¹ K. Heller,¹ R. Stahl,¹ H. Wolters,¹ I. Hauser,¹ M. Porstner,² W. Arns.¹

5:30pm-6:30pm: Factors Affecting Efficacy Outcomes at 12 and 24-Months After Kidney Transplantation in Patients from the A2309 Study

C. Escrig,¹ G. Colussi,² R. Roland,² M. Vergara,³ Z. Wang.³

5:30pm-6:30pm: Increasing Tacrolimus Exposure to Minumize Chronic Rejection: How Can We Do It? What Are the Risks?

T. Hsu,¹ J. Yin,¹ L. Awdishu,¹ J. Kerr,¹ R. Steiner.²

5:30pm-6:30pm: Influence of CYP3A5 and ABCB1 Genotypes on Pharmacokinetics of Immediate and Prolonged Release Tacrolimus Preparations

T. Elnahhas,^1,2 T. Lee,² M. Moreton,² D. McKeown,² J. Popoola,³ R. Ramkhelawon,³ A. Johnston,^1,2 I. MacPhee.³

5:30pm-6:30pm: Month 48 Follow-Up Results of HERAKLES Trial on Three Different Treatment Regimen and Switching Off Behaviour in De Novo Renal Transplant Patients

W. Arns,¹ K. Budde,¹ C. Sommerer,¹ O. Witzke,¹ M. Guba,¹ J. Jacobi,¹ B. Vogt,³ P. Reinke,¹ I. Hauser,¹ R. Stahl,¹ T. Rath,¹ D. Baeumer,² M. Porstner,² M. Zeier,¹ F. Lehner,¹ V. Kliem.¹

5:30pm-6:30pm: NFAT Regulated Cytokine Gene Expression for Immune Monitoring in Kidney Transplant Recipients

V. Tatapudi, A. Webber, C. Leung, F. Vincenti.

5:30pm-6:30pm: Once Daily Dosing Is as Effective as Twice Daily Dosing of Immediate Release Tacrolimus

L. Bowman,¹ T. Horwedel,¹ J. Hagopian,¹ B. Bone,² H. Wijeweera,² D. Brennan.²

5:30pm-6:30pm: Once-a-Day Administration of CNIs, mTOR and MMF Is Safe in De Novo Renal Transplant Recipients: 1-Year Results of a Pilot Study

G. Spagnoletti, M. Salerno, E. Favi, J. Pedroso, J. Romagnoli, F. Citterio.

5:30pm-6:30pm: Outcomes of Hispanic Kidney Transplant Recipients Under a Cyclosporine Versus Tacrolimus Based Immunosuppression Regimen

P. West-Thielke,¹ M. Campara,² A. Ladik,¹ E. Terranova,² E. Benedetti,¹ J. Thielke.²

5:30pm-6:30pm: Outcomes of Kidney Transplant Recipients Minimally Immunosuppressed: A Cohort Study Analysis

A.-H. Querard,^1,2,3 F. Gillaizeau,^2,1 G. Couvrat-Desvergne,^1,2,3 J. Dantal,^1,4,5 P. Daguin,¹ S. Le Floch,¹ S. Castagnet,⁶ S. Brouard,^1,4 Y. Foucher,^2,1 M. Giral.^1,2,4,5

5:30pm-6:30pm: Pharmacokinetics of Everolimus (EVL) in Elderly Recipients Under Low-Tacrolimus(TAC)/Everolimus in the First Year After Renal Transplantation. Data from the NEverOLd Trial

E. David-Neto,¹ P. Romano,² F. Agena,¹ P. Ebner,² A. Triboni,¹ F. Ramos,¹ N. Galante,¹ F. Lemos.¹

5:30pm-6:30pm: Pharmacokinetics of Mycophenolic Acid (MPA) in Elderly Compared to Young Recipients in the First Year After Renal Transplantation. Data from the NEverOLd Trial

P. Romano,¹ F. Agena,² P. Ebner,¹ A. Triboni,² F. Ramos,² N. Galante,² F. Lemos,² N. Sumita,¹ E. David-Neto.²

5:30pm-6:30pm: Pharmacokinetics of Tacrolimus (TAC) in Elderly Compared to Young Recipients in the First Year After Renal Transplantation. Data from the NEverOLd Trial

E. David-Neto,¹ P. Romano,² A. Triboni,¹ F. Agena,¹ P. Ebner,² F. Ramos,¹ N. Galante,¹ F. Lemos.¹

5:30pm-6:30pm: Plasma 4β-Hydroxycholesterol Measurement as a Potential Biomarker for CYP3A5 Activity in Informing Tacrolimus Dosing

T. Elnahhas,^1,2 E. de Jonge,⁴ T. Lee,² B. van Zelst,⁴ J. Popoola,³ R. Ramkhelawon,³ R. van Schaik,⁴ A. Johnston,^1,2 I. MacPhee.³

5:30pm-6:30pm: Post Hoc Subgroup Analysis of ZEUS: Outcome on Renal Function, Efficacy and Safety in Living-Donor Kidney Transplant Recipients After Conversion from a Calcineurin Inhibitor to an Everolimus Based Regimen: 5 Year Follow-Up Data

F. Lehner,¹ K. Budde,¹ R. Wuethrich,² P. Reinke,¹ W. Arns,¹ A. Muehlfeld,¹ U. Eisenberger,¹ R. Stahl,¹ K. Heller,¹ O. Witzke,¹ B. Suwelack,¹ H. Wolters,¹ I. Hauser,¹ M. Porstner,³ C. Sommerer.¹

5:30pm-6:30pm: Prospective Study of a Steroid Free, Low Dose Tacrolimus and Everolimus Combination Regimen in Kidney Transplant

A. Shetty,¹ J. Leventhal,¹ O. Traitanon,¹ A. Alvarado,¹ V. Mas,² J. Mathew,¹ E. Tantisattamo,¹ L. Gallon.¹

5:30pm-6:30pm: Reduced Intensity Immunosuppression Protocol Lowers Drug Costs and May Decrease Incidences of BK Viremia and Readmissions After Kidney and Kidney/Pancreas Transplant

M. Mariski,¹ A. DeGolovine,² W. Dar,² J. Bynon,² H. Adrogué,² M. Hobeika.²

5:30pm-6:30pm: Reduction of Tacrolimus With Everolimus Addition in Maintenance Immunosuppression Improves Calcineurin Inhibitor-Induced Arteriolopathy in Kidney Allografts

M. Miura,¹ H. Higashiyama,¹ Y. Fukasawa.²

5:30pm-6:30pm: Safety and Efficacy of Low Dose and Very Low Dose Extended-Release Tacrolimus / MMF in De Novo Kidney Transplant Recipients

Y. Watarai,¹ M. Okada,¹ K. Futamura,¹ K. Ito,¹ T. Yamamoto,¹ M. Tsujita,¹ T. Hiramitsu,¹ N. Goto,¹ S. Narumi,¹ T. Kobayashi.²

5:30pm-6:30pm: Steroid-Free Quadruple Induction Regimen With Basiliximab, Everolimus, Mycophenolate and Very Low Dose Tacrolimus Reduces Incidence of Biopsy-Proven Acute Rejection and Toxicity Profile Compared to the Standard Triple Regimen

M. Miura, H. Higashiyama.

5:30pm-6:30pm: Superior Renal Function in an Everolimus-Based Calcineurin Inhibitor Free Regimen Compared to Standard Cyclosporine/Mycophenolate and Low Cyclosporine/Everolimus: Follow-Up of the HERAKLES Study at Month 48

K. Budde,¹ C. Sommerer,¹ P. Weithofer,¹ O. Witzke,¹ M. Guba,¹ J. Jacobi,¹ B. Vogt,³ I. Hauser,¹ R. Stahl,¹ P. Reinke,¹ T. Rath,¹ D. Baeumer,² M. Porstner,² M. Zeier,¹ F. Lehner,¹ W. Arns.¹

5:30pm-6:30pm: Treatment With Everolimus and Reduced-Exposure Cyclosporine Is Efficacious in De Novo Renal Transplant Recipients at Increased Risk for Efficacy Failure: Post-Hoc Analysis from the A2309 Study

M. Carmellini,¹ V. Garcia,¹ Z. Wong,² M. Vergara,² C. Escrig,² G. Russ.¹

5:30pm-6:30pm: mTOR-Based CNI Minimization Vs Withdrawal in African American Kidney Transplant Recipients

J. Fleming,¹ D. Taber,² N. Pilch,¹ H. Meadows,¹ C. Mardis,¹ J. McGillicuddy,² S. Nadig,² K. Chavin,² P. Baliga,² C. Bratton.²

« View all sessions from the 2015 American Transplant Congress